INTREPAD stands for Investigation of Naproxen TReatment Effects in Pre-symptomatic Alzheimer’s Disease.

This trial was intended to determine if a low dose of an anti-inflammatory drug would change the trajectory of the presymptomatic progression of AD. This presymptomatic progression was tracked by a multimodal composite score, the Alzheimer Progression Score.

See the recently published results paper, here.

  • Duration: Two-year
  • Design: Randomized, placebo-controlled, double-masked
  • Study drug: naproxen sodium 220 mg b.i.d, versus placebo (1:1)
  • Population: PREVENT-AD participants, enrolled: n=195, included in analysis n=160

Recruitment is completed, trial ended March 2017

Clinical NCT-02702817